Pradžia › Vėžys (visų tipų) › Oklahoma
Vėžys (visų tipų) klinikiniai tyrimai Oklahoma
15 tyrimai dėl Vėžys (visų tipų) ieško dalyvių vietose Oklahoma.
Miestai Oklahoma
Oficialus tyrimo tekstas (anglų kalba)
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
- OU Health - Stephenson Cancer Center /ID# 277656, Oklahoma City
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Moterims · Atnaujinta 2026-10-01 · NCT07024784Registry Study for Radiation Therapy Outcomes
- Oklahoma Proton Center, Oklahoma City
Renkami dalyviaiStebimasis tyrimas
Visi amžiai · Visoms lytims · Atnaujinta 2026-09-29 · NCT01255748Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- University of Oklahoma, Oklahoma City
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-22 · NCT06128551Prospective Study to Assess a Diagnostic Aid for Cancer
- Hightower Clinical, Oklahoma City
Renkami dalyviaiStebimasis tyrimas
Amžius 45 ir vyresni · Visoms lytims · Atnaujinta 2026-09-21 · NCT07046260Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
- University of Oklahoma Peggy and Charles Stephenson Cancer Center, Oklahoma City
Renkami dalyviai2/3 fazė
Visi amžiai · Visoms lytims · Atnaujinta 2026-09-18 · NCT03435796A Phase 1/1b Study of IAM1363 in HER2 Cancers
- OU Health Stephenson Cancer Center, Oklahoma City
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-09 · NCT06253871Project: Every Child for Younger Patients With Cancer
- University of Oklahoma Health Sciences Center, Oklahoma City
- Saint Francis Children's Hospital, Tulsa
Renkami dalyviaiStebimasis tyrimas
Iki 25 metų · Visoms lytims · Atnaujinta 2026-08-25 · NCT02402244Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
- University of Oklahoma Health Sciences Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-07 · NCT06580314Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
- Mercy Hospital - OKC, Oklahoma City
Renkami dalyviaiStebimasis tyrimas
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-06-29 · NCT07327489GEMINI-NSCLC: NSCLC Biomarker Study
- Hightower Clinical, Oklahoma City
- Mercy Clinic Oncology and Hematology - Coletta, Oklahoma City
- Oklahoma Cancer Specialists and Research Institute, Tulsa
Renkami dalyviaiStebimasis tyrimas
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-02-05 · NCT05236114Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
- Oklahoma University Stephenson Cancer Center, Oklahoma City
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2025-11-13 · NCT05997017SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Tulsa
Renkami dalyviaiStebimasis tyrimas
Visi amžiai · Visoms lytims · Atnaujinta 2025-10-28 · NCT03452774A Study of NX-1607 in Adults With Advanced Malignancies
- University of Oklahoma, Oklahoma City
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2025-09-09 · NCT05107674Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays
- Mercy Clinic Oncology and Hematology - Coletta, Oklahoma City
Renkami dalyviaiStebimasis tyrimas
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2025-05-06 · NCT05234177Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
- OUHSC Stephenson Cancer Center, Oklahoma City
- Mercy Health Center - Oncology Hematology, Oklahoma City
Renkami dalyviai
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2024-11-27 · NCT03860883Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.